Trial Profile
A Phase I, First-in-Human, Randomized, Subject and Investigator-Blind, Sponsor Open, Single Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pf-04958242 in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2019
Price :
$35
*
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Biogen; Pfizer
- 25 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Aug 2010 Status changed from 'not yet recruiting' to 'recruiting', according to ClinicalTrials.gov